Find Academic Supervisors

Liam HeaneyView profile

Senior Lecturer

• Bioanalytical Science
• Analytical Chemistry
• Clinical Diagnostics
• +5 more

Liam Heaney is a Senior Lecturer in Bioanalytical Science at Loughborough University's School of Sport, Exercise & Health Sciences. He joined in 2018 through the Loughborough Excellence 100 scheme and was promoted in 2022. His expertise lies in high-throughput metabolite biomarker analysis using mass spectrometry, with applications in clinical diagnostics, sports anti-doping, and exercise performance monitoring. He holds a BSc/MSc in Sport and Exercise Science/Exercise Physiology and a PhD in Analytical Chemistry from Loughborough University. Research Interests: Development of analytical methods for small molecule metabolites Clinical and sports-related biomarker discovery Gas/Liquid Chromatography-Mass Spectrometry applications Anti-doping analysis and ethical biomonitoring Publications: Liam's work emphasizes metabolomics and ambient ionization techniques, contributing to both clinical and sports science. Recent studies focus on cannabidiol pharmacokinetics, SCFA supplementation, and TMAO metabolism in health/disease. Recipient of The Analytical Scientists 40 Under 40 Power List (2022) Labs/Teams: Active in Sport Performance and Lifestyle for Health & Wellbeing research groups. Collaborates with the John van Geest Biomarker Facility (Leicester) and NIHR Cardiovascular Biomedical Research Centre.

Patrick GunningView profile

Professor

• Biological Chemistry
• Organic Chemistry
• Protein-Protein Interactions
• +7 more

Patrick Gunning is a Professor at the University of Toronto (Mississauga campus), specializing in Biological Chemistry and Organic Chemistry. His research focuses on developing small molecule architectures to manipulate protein complexation events, particularly targeting aberrant protein interactions in diseases like cancer. Key areas include STAT3/STAT5 inhibition, histone deacetylase (HDAC) modulation, and molecular design strategies for cancer therapies. Research interests emphasize understanding protein-protein interaction 'hot spots' and designing drugs to suppress or enhance specific gene expressions. His work explores both organic and inorganic drug-like scaffolds to regulate cellular signaling pathways. Recent studies highlight novel treatments for leukemia, lymphoma, and brain metastases through targeted protein degradation and metabolic pathway manipulation. Over 50 publications demonstrate expertise in oncology, epigenetics, and drug discovery. Notable contributions include HDAC6-selective inhibitors, PROTAC-based degraders, and fluorine NMR methodologies for protein analysis. His interdisciplinary approach bridges organic chemistry, biochemistry, and clinical applications in precision medicine. Current projects investigate molecular mechanisms underlying cancer growth, with a focus on STAT signaling pathways and metabolic vulnerabilities. The lab also pioneers innovative drug delivery strategies using advanced spectroscopic techniques and chemical synthesis platforms.

• Analytical Chemistry
• Bioanalytical Chemistry
• Capillary Electrophoresis
• +5 more

Lisa Holland is a Professor in the C. Eugene Bennett Department of Chemistry at West Virginia University (WVU), affiliated with the Eberly College of Arts and Science. She holds a Ph.D. from the University of North Carolina at Chapel Hill and has been a faculty member at WVU since 2002. Her research focuses on developing miniaturized analytical separation techniques, particularly capillary electrophoresis and microfluidics, to analyze biological pharmaceuticals, glycans, nanoparticles, and disease markers. She leads the Holland Group, which collaborates with institutions like The Ohio State University and NIOSH. Education: B.S., Chemistry, University of Maryland, College Park Ph.D., Analytical Chemistry, University of North Carolina at Chapel Hill Postdoctoral Fellowship, University of Kansas (Pharmaceutical Chemistry) Research Interests: Her work emphasizes bioanalytical methods for characterizing biopharmaceuticals, glycosylation patterns, and viral enzymes. Techniques include capillary electrophoresis with nanogel matrices, mass spectrometry interfacing, and low-cost microfluidic devices for education and diagnostics. Publications & Awards: Over 50 peer-reviewed articles, with recent work on nanogel-based enzyme assays and microfluidic educational tools. Recognized with NIH R01 and NSF awards. Active in professional societies like the American Chemical Society. Grants & Leadership: Principal Investigator on projects funded by NIH, NSF, and industry. Served as Chair of the ACS Chromatography Division. Developed REU programs to engage undergraduates in nanotechnology research. Labs/Teams: Leads the Holland Group at WVU, focusing on bioanalytical chemistry and separation science. Collaborates with multidisciplinary teams in nanotechnology, virology, and environmental analysis.

Robert N. BenView profile

Professor

• Organic Chemistry
• Bioorganic Chemistry
• Carbohydrate Chemistry
• +5 more

Robert N. Ben is a Full Professor in the Department of Chemistry and Biomolecular Sciences at the University of Ottawa. His research focuses on organic and bioorganic chemistry, particularly the development of small-molecule ice recrystallization inhibitors (IRIs) for improving cryopreservation techniques. These inhibitors enhance the viability of cells, tissues, and biological systems during freezing and thawing processes, with applications in regenerative medicine, stem cell therapy, and biomedical engineering. He holds a B.Sc. from Laurentian University (1990) and a Ph.D. from the University of Ottawa (1994). His work bridges synthetic chemistry and biological applications, aiming to design cryoprotectants with enhanced stability and activity for medical and industrial uses. Key research areas include asymmetric synthesis of bioactive compounds, carbohydrate chemistry, and glycoprotein design. Ben’s lab investigates the structure-activity relationships of IRIs, their mechanisms of action, and their utility in preserving diverse biological materials, including red blood cells, stem cells, and tissues. His contributions have advanced understanding of how small molecules mitigate ice crystal growth, reducing cryopreservation damage in cellular therapies and organ preservation. Despite no listed awards, his prolific research output (over 50 publications from 2013–2024) highlights his leadership in cryopreservation science. He advises students in synthetic and bioorganic chemistry but no specific advisees are named in the provided texts. Current projects emphasize translating IRI-based technologies into clinical applications, such as improving platelet and cord blood storage.

Alessandro BertucciView profile

Associate Professor

• DNA Nanotechnology
• Analytical Chemistry
• Biomolecular Engineering
• +5 more

Prof. Alessandro Bertucci is an Associate Professor at the University of Parma, Department of Chemical, Life and Environmental Sustainability Sciences, specializing in Analytical Chemistry (CHIM/01). He earned his Ph.D. in Chemical Sciences through a dual Italian-French program at the University of Parma and the University of Strasbourg, receiving the "Best Scientific Thesis in France" award. Education: Master's in Chemistry (2011, University of Parma), Ph.D. in Chemical Sciences (2015, University of Parma/Strasbourg) Postdoctoral Experience: University of Rome Tor Vergata (2015-2016), Sanford Burnham Prebys Medical Institute (2016), University of Melbourne (2016), UC San Diego (2017-2020) His research integrates molecular recognition with synthetic design for biomolecular systems programming , focusing on nanoscale diagnostics and precision medicine . Key methodologies include DNA nanotechnology, electrochemical biosensing, and responsive nanomaterials. Recent publications highlight CRISPR-based diagnostics and low-cost spectrophotometric platforms . His work has been recognized with the Galileo Galilei International Prize (2021) and ISSNAF Young Investigator Finalist (2018). Scientific Awards: Galileo Galilei Prize (2021), ISSNAF Finalist (2018) Fellowships: Marie Skłodowska-Curie Global Fellowship (2017), Endeavour Research Fellowship (2016), Umberto Veronesi Fellowship (2020) He teaches Bioanalytical Methods (Master's in Genomic, Molecular and Industrial Biotechnology) and Analytical Chemistry for Materials (Bachelor's in Materials Science), with extensive experience in course coordination and curriculum development.

Zhang YangView profile

Associate Professor

• Artificial Intelligence in Biomedical Imaging
• Deep Learning for Omics Data Analysis
• Pathogen Detection and Diagnostics
• +7 more

Zhang Yang is an Associate Professor at the School of Medical Engineering, Harbin Institute of Technology (Shenzhen), with a joint appointment as Visiting Professor at the University of Tokyo starting in July 2024. He holds a PhD from the University of Cambridge's Department of Pathology and an M.Phil. from the University of Hong Kong's HKU-Pasteur Research Center. Previously, he served as an Assistant Professor at Harbin Institute of Technology (Shenzhen) from September 2015 to December 2020. His research integrates computational and experimental approaches to address challenges in pathogen and cancer research. On the computational side, his work focuses on developing AI-powered microscopic imaging systems, applying deep learning to analyze multi-omics data (including proteins, DNA, miRNAs, LncRNAs, and mRNAs), and utilizing deep learning in cheminformatics for drug discovery. On the experimental side, his laboratory combines imaging, high-throughput sequencing, mass spectrometry, and chemical biology to understand disease mechanisms at the molecular level. His publication record demonstrates significant impact, with over 50 SCI-indexed papers in high-impact journals including Nature Communications, Briefings in Bioinformatics, Bioinformatics, Analytical Chemistry, and Trends in Biotechnology. His work has been cited by prestigious journals such as Nature Reviews Methods Primers and Nature Communications, with three ESI highly cited papers. His research spans multiple interdisciplinary fields, combining artificial intelligence with biomedical applications to advance diagnostic and therapeutic approaches. World's Top 2% Scientists 2021 Fellow of the Royal Society of Biology Three ESI Highly Cited Papers Five authorized national invention patents As an academic leader, he serves as Associate Editor for BMC Biology and Frontiers in Microbiology, Academic Editor for PLOS Genetics, Editorial Board Member for Communications Biology, and Guest Editor for a Special Issue on AI in analytical chemistry in Trends in Analytical Chemistry. His laboratory actively collaborates with international institutions, with graduates pursuing further studies at Hong Kong Chinese University, Hong Kong University of Science and Technology, Hong Kong Polytechnic University, Macau University, and the University of New South Wales. He teaches Introduction to Modern Biology for undergraduates and Bioanalytical Chemistry for graduate students.

Joseph RowerView profile

Academic

• Pharmacokinetics-Pharmacodynamics (PK-PD) Relationships
• Bioanalytical Methods Development
• Pediatric Clinical Pharmacology
• +7 more

Dr. Joseph Rower is a Research Assistant Professor in the Department of Pharmacology and Toxicology and Adjunct Assistant Professor in Pediatrics at the University of Utah's College of Pharmacy. He serves as Associate Director of the Center for Human Toxicology. Undergraduate: California Lutheran University, BS in Chemistry and Mathematics Doctoral: University of Colorado Anschutz Medical Campus, PhD in Pharmaceutical Sciences Postdoctoral Fellowships: Systems Biology at University of Colorado, Antiviral Pharmacology at University of Colorado, and Pediatric Clinical Pharmacology at University of Utah Dr. Rower's research focuses on pediatric pharmacology , particularly validating bioanalytical methods for small blood volumes to improve clinical care for children. His lab explores personalized dosing strategies , tacrolimus in pediatric transplantation , (val)ganciclovir for congenital cytomegalovirus , and cannabis pharmacokinetics in adolescents . Collaborative work spans preclinical models, clinical trials, and pharmacometric modeling. Recent publications emphasize pediatric pharmacokinetic-pharmacodynamic relationships , bioanalytical innovations , and personalized medicine applications in diverse areas including infectious disease , neurology , and critical care . Scientific Awards Board-certified clinical pharmacologist (Diplomate of the American Board of Clinical Pharmacology) Dr. Rower's lab within the Center for Human Toxicology integrates bioanalysis and pharmacometrics to identify patient-specific factors affecting drug pharmacokinetics. Collaborations include Dr. Albert Park (pediatric ENT), Dr. Chris Reilly's team (TRP channels and pulmonary toxicology), and international partners via the University of Utah's cores.

• Organic Chemistry
• Chemical Biology
• Peptide and Protein Synthesis
• +5 more

Professor Richard J. Payne (FAA, FRSC, FRSN, FRACI) is the NHMRC Investigator Leadership Fellow and Deputy Director of the ARC Centre of Excellence for Innovations in Peptide and Protein Science at The University of Sydney. He earned a BSc (1st class honours) from the University of Canterbury (2002) and a PhD from the University of Cambridge under the late Professor Chris Abell (2003-2007). After postdoctoral work at The Scripps Research Institute with Professor Chi-Huey Wong (2007-2008), he joined The University of Sydney as a Lecturer in Organic Chemistry. His research focuses on chemical synthesis of biomolecules to address biological and medical challenges, particularly in anti-infectives , vaccine development , and glycopeptide engineering . His lab pioneered diselenide-selenoester ligation and selenocysteine-based modification techniques for constructing complex peptides and proteins. Current projects target pathogens like Mycobacterium tuberculosis , Plasmodium falciparum , and SARS-CoV-2 through inhibitor design , anticoagulant discovery , and LYTAC development . His 15 most recent publications span 2025-2021 and reflect multidisciplinary work at the chemistry-biology interface , including antiviral peptides , glycoprotein assembly , and supramolecular anticoagulants . Notably, 2025 articles address C-terminal bromodomain inhibitors and on-demand reversible anticoagulants , while 2024 studies focus on PROTAC-based proteostasis disruption and mycobacterial chaperone targeting . Awards & Honors 2016 Malcolm McIntosh Prime Minister's Prize 2023 Australian Academy of Science Fellowship 2014 Le Fèvre Memorial Prize & Edgeworth David Medal 2018 A.J. Birch Medal He supervises 8 active research students and leads collaborations with The Payne Research Group , Charles Perkins Centre , and Sydney Nano Institute . His work aligns with the University of Sydney's research strengths in Molecules to Materials and Next Generation Therapeutics .

Ashley RossView profile

Associate Professor

• Electrochemistry
• Microfluidics
• Neurochemistry
• +3 more

Dr. Ashley Ross is an Associate Professor in the Department of Chemistry at the University of Cincinnati, where she leads research in bioanalytical chemistry. She holds a Ph.D. in Analytical Chemistry from the University of Virginia (2014) and a B.S. in Chemistry from Christopher Newport University (2009). Her research group focuses on developing electrochemical methods and microfluidic platforms to study neuro-immune communication. Research interests include: (1) Developing electrochemical sensors for neurotransmitter detection in brain and immune systems; (2) Designing novel carbon nanomaterials for enhanced electrochemical sensing; (3) Creating microfluidic organ-on-chip platforms for studying neuro-immune interactions. Her work bridges analytical chemistry, neuroscience, and immunology. Her recent publications demonstrate a strong focus on advanced electrochemical sensing techniques, novel carbon nanomaterial development, and microfluidic platforms for neurochemical analysis. Research consistently addresses real-time monitoring of neurotransmitters and neuroimmune interactions. Major Awards: Alfred P. Sloan Fellowship (2022) NSF CAREER Award (2022) RCSA Microbiome, Neurobiology, and Disease Fellow (2021) American Association of Immunologists Careers in Immunology Fellowship Top 40 under 40 in Analytical Chemistry Active Grants: NIH R01AI151552: Monitoring neurochemical signaling dynamics in lymph node ($1.9M) NIH R01NS121426: Monitoring rapid guanosine signaling during ischemia ($1.9M) NSF CAREER: Tunable graphene microelectrodes for sensing ($300K) RCSA Award: Unraveling microbiota-neuron communication in aging ($55K) Dr. Ross directs the Ross Lab (www.rosslabuc.com), which develops analytical tools for neuroimmune communication research. The lab utilizes electrochemistry, microfluidics, and materials science to advance understanding of brain-immune interactions.

Albert SickmannView profile

Professor

• Proteomics
• Bioanalytics
• Analytical Chemistry
• +5 more

Albert Sickmann is a Professor of Applied Proteomics and Bioanalytics at Ruhr-Universität Bochum and Director of the Bioanalytics Department at the Leibniz Institute for Analytical Sciences (ISAS) in Dortmund. He serves as Chairman of ISAS’s Board of Directors and leads the Proteomics research group. His research focuses on quantitative analysis of post-translational modifications, protein networks, and developing analytical methods for precision medicine. He completed his PhD at Ruhr-Universität Bochum on 'Proteome Analysis of Human Cerebrospinal Fluid' and held positions at the Rudolf Virchow Centre in Würzburg before returning to his alma mater in 2008. His recent work includes optimizing detergent-based proteome profiling and investigating the effects of spermidine supplementation on aging. Key publications include advancements in hybrid detergent applications for protein solubilization and studies on dietary interventions in aging models. Notably, his research on hybrid detergents demonstrated a significant increase in observable protein identities in E. coli proteomes. Funding sources include grants from North Rhine-Westphalia’s Ministry of Culture and Science, the Academy of Sciences, and industry collaborations. His lab at ISAS is a hub for proteomic innovation, emphasizing interdisciplinary approaches to biomedical challenges.

• Soil Biogeochemistry
• Soil Carbon/Nutrient Cycling
• Greenhouse Gas Emissions
• +4 more

Dr. Yunying Fang is a Senior Lecturer at Griffith University's School of Environment and Science, affiliated with the Australian Rivers Institute. She holds a PhD from the University of Sydney and previously worked at the NSW Department of Primary Industries (2013–2023). Her research focuses on Soil Biogeochemistry, Soil Carbon/Nutrient Cycling, and Greenhouse Gas Emissions, with an emphasis on Nature-Based Solutions to Climate Change and Soil Health Resilience. Education: PhD in Soil Science, University of Sydney Research Interests: Soil Carbon Sequestration Mechanisms Impact of Land Management and Climate Change on Ecosystem Processes Stable Isotope Methodologies for Soil Amendment Studies Funded Projects (Selected): Developing Standard Protocols for Microplastics in Soils (Solving Plastic Waste CRC, 2025–2028) Climate Change Effects on Phosphorus Cycling (Griffith University Internal Grant, 2023) Innovative Microbial Carrier Products Evaluation (High Performance Soils CRC, 2023–2026) Teaching & Supervision: Associate Supervisor for doctoral projects on Land Management in Rubber-Based Systems and Organic Amendments in Soil Carbon Sequestration Affiliations: Member of Australian Rivers Institute Research Entity Griffith Sciences Group

Henning UrlaubView profile

Professor

• Mass Spectrometry
• Proteomics
• Protein Interactions
• +7 more

Prof. Henning Urlaub is a Professor at the Faculty of Medicine at Georg August University Göttingen and Group Leader of the Bioanalytical Mass Spectrometry Group at the Max Planck Institute for Multidisciplinary Sciences (formerly Max Planck Institute for Biophysical Chemistry). His roles include leading a research group focusing on proteomics and clinical biochemistry at the University Medical Center Göttingen (UMG). He holds dual affiliations in both academic and clinical research sectors. He earned his Ph.D. in biochemistry from the Free University of Berlin (1993–1996) and conducted postdoctoral research at institutions including the Max Delbrück Center for Molecular Medicine (Berlin) and the Philipps University of Marburg. His career includes leadership roles since 2010 in both the Max Planck Institute and UMG. Research Interests : Dr. Urlaub’s work centers on modern mass spectrometry applications for analyzing proteins, post-translational modifications, and protein interactions. Key projects include: Quantitative analysis of synaptic proteins under stimulation Protein cross-linking studies in B cells and other systems Method development for protein-RNA/DNA interactions Structural elucidation of large complexes via CX-MS and cryo-EM His group operates as a core proteomics facility for the Max Planck Institute and collaborates with external institutions like the University Hospital Frankfurt. They also maintain a clinical proteomics branch at the UMG’s Institute for Clinical Chemistry. Collaborations & Infrastructure : The group provides proteomics services to researchers across disciplines, emphasizing translational and clinical applications. Their instrumentation includes advanced mass spectrometry platforms (e.g., ESI, MALDI) for high-throughput proteomic analysis.

Jared L. AndersonView profile

Professor

• Separation Science
• Analytical Chemistry
• Bioanalytical Chemistry
• +7 more

Jared L. Anderson serves as the Alice Hudson Professor in the Department of Chemistry at Iowa State University, where he leads an active research group focused on advancing separation science and analytical chemistry. His laboratory develops innovative approaches to chemical measurement and analysis using ionic liquids, polymeric ionic liquids, and magnetic ionic liquids for applications in pharmaceutical analysis, environmental monitoring, and nucleic acid diagnostics. Dr. Anderson's research interests center on separation science with particular emphasis on the application of ionic liquids in chromatographic separations and sample preparation. His group has pioneered techniques using magnetic ionic liquids for nucleic acid extraction, developed novel stationary phases for comprehensive two-dimensional gas chromatography, and created polymeric ionic liquid-based sorbent coatings for solid-phase microextraction. These innovations address critical challenges in pharmaceutical quality control, particularly in the analysis of genotoxic impurities in active pharmaceutical ingredients. His recent publications demonstrate a strong focus on practical analytical solutions, with research trending toward point-of-care diagnostic applications using smartphone technology, 3D printed extraction devices, and advanced nucleic acid analysis techniques. The work bridges fundamental chemistry with real-world applications in food safety, environmental monitoring, and clinical diagnostics. Dr. Anderson actively mentors graduate students and postdoctoral researchers, with several former trainees securing competitive academic positions and industry roles. His group maintains collaborations with academic research groups across Europe, South America, North America, and Asia, as well as numerous industrial partners in the pharmaceutical sector. The laboratory participates in the ACS Project SEED program, providing research opportunities for underrepresented high school students. The Anderson Research Group operates state-of-the-art facilities for developing and testing novel separation methodologies, with particular expertise in gas chromatography, liquid chromatography, and microextraction techniques. Current projects focus on creating tunable solvents for specific analytical challenges, with applications spanning from pharmaceutical quality control to environmental monitoring and clinical diagnostics.

John LukeshView profile

Associate Professor

• Chemical Biology
• Medicinal Chemistry
• Synthetic Organic Chemistry
• +3 more

John Lukesh is an Associate Professor in the Department of Chemistry at Wake Forest University, Winston-Salem, NC. His research at the intersection of synthetic organic chemistry and biology focuses on designing redox-active molecules with therapeutic potential. Ph.D., University of Wisconsin–Madison (2014), under Ronald T. Raines Postdoctoral work, The Scripps Research Institute (2014–2017), with Dale L. Boger Research Interests: The Lukesh lab develops novel redox-active molecules, emphasizing their applications in chemical biology and medicine. Key areas include: Chemical Biology: Probing reactive sulfur/selenium species in biological systems Medicinal Chemistry: Selenium-containing scaffolds for redox-based therapeutics Synthetic Methodology: Organoselenium reagents for heterocyclic synthesis via C–C bond formation Publications highlight his work on hydrogen sulfide (H2S) and hydrogen selenide (H2Se) donors, ROS-responsive probes, and selenium-mediated synthetic methods. His awards include: NSF CAREER Award (2022–2027) NIH NIGMS MIRA (2024–2029) F. M. Kirby Family Faculty Fellowship (2022–2025) Wake Forest Award for Excellence in Research (2025) His lab website ( lukeshjc.sites.wfu.edu ) details ongoing projects in redox chemistry and biological applications.

Carsten HopfView profile

Professor

• Bioanalytics
• Drug Discovery
• Mass Spectrometry Imaging
• +6 more

Carsten Hopf is a Professor of Bioanalytics and Drug Discovery at Mannheim University of Applied Sciences, leading the Institute of Instrumental Analytics and Bioanalytics and the CeMOS (Center for Mass Spectrometry and Optical Spectroscopy). His work focuses on developing spatially resolved omics technologies (e.g., MALDI-MS imaging) for neurodegenerative and oncological research. He explores lipidomics, proteomics, and metabolomics to understand Alzheimer's disease, glioblastoma, and other neurodegenerative disorders. Key projects include the SMART-CARE-2 BMBF initiative (2023–2026) and DFG-funded research on spatial multi-omics in glioblastoma (SFB 1389). Research interests center on mass spectrometry innovations, including matrix optimization, AI-driven data analysis, and multimodal imaging (e.g., infrared microscopy integration). His lab develops label-free cell assays for drug discovery and studies molecular mechanisms of neurodegeneration. Collaborations span academia and industry, with projects like the M 2 Aind partnership addressing 3D cell culture toxicity assessments. Grants include BMBF, DFG, and EU funding for systems medicine, organoid analysis, and mass spectrometry cores. His technological advancements aim to improve biomarker discovery and translational medicine in neuro-oncology and neurodegeneration.